Elevance Health Inc

Institutional investors buy more Elevance Health shares amid rising health‑insurance premiums. Discover why ELV’s quiet activity matters for investors, hospitals, and policy makers.

Vanguard’s stake in Elevance Health signals confidence in the insurer’s tech‑driven, value‑based strategy and highlights key market shifts shaping U.S. health‑insurance profitability.

Elevance Health’s recent insider option exercises reveal executive confidence and a focus on value‑based care, data‑driven strategy, and strong financial stewardship.

AN2 Therapeutics’ recent option exercises show executive confidence yet minimal dilution, while strategic reimbursement plans aim to boost revenue and patient access in the biotech sector.

Elevance Health’s stock dips as CMS freezes Medicare Advantage and drug‑plan enrollment—learn how these rules could reshape the insurer’s growth and strategy.

Elevance Health’s new leadership reshapes care delivery, cutting pharma costs with data‑driven utilization, AI‑enhanced portals, and a $2 M food‑as‑medicine pledge.

Elevance Health’s new CTO and “Food as Medicine” expansion show how tech-driven engagement and preventive care can cut costs, boost value‑based outcomes, and win members in a shifting US health market.

Elevance Health’s stock dips amid regulatory scrutiny—learn why the subpoena could reshape its valuation, risk profile, and competitive edge in U.S. health‑care insurance.

Institutional investors back Elevance Health amid Medicare policy uncertainty, highlighting strong balance sheet, value‑based care strategy, and attractive 12x P/E for potential upside.

Elevance Health Inc. will release Q1 2026 earnings at its January conference, with modest EPS growth expected and a $12.8 million settlement resolving residential‑treatment coverage denials—key insights for insurers, patients, and providers.